Osocimab, formerly known as BAY 1213790, represents a unique monoclonal antibody currently undergoing clinical assessment for the therapy of multiple hematologic cancers. This agent specifically targets CD38, a surface https://mariamrtzi219858.mpeblog.com/74178268/osocimab-a-deep-analysis-into-bay-1213790-and-its-outlook